Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 May 2022
VenoStent technology receives breakthrough device designation by FDA
17 May 2022 - Designation to promote more rapid agency and market access for VenoStent. ...
Posted by Michael Wonder on 17 May 2022
Understanding ‘evergreening’: making minor modifications of existing medications to extend protections
17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known ...
Posted by Michael Wonder on 17 May 2022
United Kingdom MHRA grants marketing authorisation for FYB201, Formycon's biosimilar for Lucentis
17 May 2022 - Formycon and its license partner Bioeq announce that today the MHRA has granted marketing authorisation in the ...
Posted by Michael Wonder on 17 May 2022
MHRA approves faricimab through international work-sharing initiative
17 May 2022 - It is the first treatment approved by the UK regulator that has been made possible through the ...
Posted by Michael Wonder on 17 May 2022
Ethical considerations for the inclusion of patient reported outcomes in clinical research
17 May 2022 - An international consensus Delphi process was developed according to the Enhancing the Quality and Transparency of Health ...
Posted by Michael Wonder on 17 May 2022
FDA expands eligibility for Pfizer-BioNTech COVID-19 vaccine booster dose to children 5 through 11 years
17 May 2022 - Today, the U.S. FDA amended the emergency use authorisation for the Pfizer-BioNTech COVID-19 vaccine, authorising the use ...
Posted by Michael Wonder on 17 May 2022
Dental AI start-up wins second FDA clearance to detect top oral diseases
16 May 2022 - The FDA has awarded dental AI start-up Overjet with landmark clearance to use its software to ...
Posted by Michael Wonder on 17 May 2022
Health economic assessment of Xevudy for the treatment of COVID-19
17 May 2022 - TLV has produced a health economic assessment for the regions for the drug Xevudy (sotrovimab). ...
Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 17 May 2022
Governor Hochul announces new watchdog bureau to tackle prescription drug costs
11 May 2022 - New pharmacy benefits bureau to supervise unregulated pharmacy benefit manager industry. ...
Posted by Michael Wonder on 17 May 2022
Finerenone for treating chronic kidney disease in people with type 2 diabetes
17 May 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 May 2022
International regulators and WHO: support health care professionals to enhance public confidence in COVID-19 vaccines
17 May 2022 - the EMA has endorsed a statement for health care professionals jointly developed by the International Coalition ...
Posted by Michael Wonder on 17 May 2022
The drugs that give her life cost more than half the family's income
18 May 2022 - For Vickie Hudson-Craig, this year’s Budget could mean the difference between life and death. ...
Posted by Michael Wonder on 17 May 2022
FDA authorises first COVID-19 test available without a prescription that also detects influenza and RSV
16 May 2022 - The EUA authorises at home sample collection with testing performed in a laboratory. ...
Posted by Michael Wonder on 17 May 2022
MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
17 May 2022 - Authorisation of the treatment is based on results from the Phase 3 trial. ...